immuno oncology frontiers world miami


Robert Piperno

Robert Piperno

QA Director, Cell & Gene Therapies, GlaxoSmithKline
Rob Piperno is Director QA, Cell and Gene Therapies at GSK.  In this role he is responsible for the building GSK’s quality systems to support the supply of GSK’s Cell and Gene Therapy products from clinical trials though to commercialization.  Prior to joining GSK R&D in 2012, Rob worked in the GSK corporate audit group supporting internal biopharmaceutical and vaccine sites.  Prior to joining GSK in 2009, Rob held numerous roles within the Johnson and Johnson biopharmaceutical QA organization.  He holds a Master degree in Biology from Rutgers University and a MBA in Pharmaceutical Marketing from St. Joseph’s University
  • "Great venue to solidify and harmonize on the current challenges facing this sector - in real time. The caliber of the speakers and session contents was premier. “
    Dolores Baksh
    Innovation Leader, GE Healthcare
  • “A great event to learn about the hurdles that are needed to be overcome to get through the clinic.”
    Devin Bridgen
    Scientist, strategic partnerships, SQZ Biotech
  • "It was a great opportunity to share current data and thinking about the development of therapeutics directed at modulating the immune response to cancer."
    Lance Leopold
    Vice President, Head of Oncology Development, Incyte Corporation
  • "Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field."
    Dr James Trager
    Vice President, Research & Product Development, Dendreon
  • “In the rapidly moving Advanced Therapy market, Phacilitate remains one of the premier events.”
    David James
    CEO, Scinogy